Natixis Asset Management boosted its stake in Clorox Co (NYSE:CLX) by 7.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,044 shares of the company’s stock after buying an additional 470 shares during the period. Natixis Asset Management’s holdings in Clorox were worth $814,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Palo Capital boosted its stake in shares of Clorox by 16.6% in the third quarter. Palo Capital now owns 2,920 shares of the company’s stock valued at $337,000 after buying an additional 415 shares during the last quarter. Gerstein Fisher bought a new stake in shares of Clorox during the third quarter valued at about $210,000. EQIS Capital Management boosted its stake in shares of Clorox by 450.7% in the fourth quarter. EQIS Capital Management now owns 5,402 shares of the company’s stock valued at $685,000 after buying an additional 4,421 shares during the last quarter. Hollencrest Securities boosted its stake in shares of Clorox by 0.4% in the fourth quarter. Hollencrest Securities now owns 5,008 shares of the company’s stock valued at $636,000 after buying an additional 22 shares during the last quarter. Finally, First National Bank of Mount Dora boosted its stake in shares of Clorox by 1.1% in the fourth quarter. First National Bank of Mount Dora now owns 4,634 shares of the company’s stock valued at $588,000 after buying an additional 50 shares during the last quarter.

Clorox Co (NYSE:CLX) traded up 1.35% during trading on Friday, reaching $127.59. The company had a trading volume of 822,319 shares. The company has a market capitalization of $16.47 billion and a P/E ratio of 25.53. The firm’s 50 day moving average is $127.67 and its 200-day moving average is $119.32. Clorox Co has a 12 month low of $103.77 and a 12 month high of $131.78.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Monday, November 2nd. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.14. The firm had revenue of $1.39 billion for the quarter, compared to analyst estimates of $1.37 billion. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.10 earnings per share. On average, equities analysts expect that Clorox Co will post $4.88 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 12th. Shareholders of record on Wednesday, January 27th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend is Monday, January 25th.

Several analysts have issued reports on the company. RBC Capital upped their target price on Clorox from $115.00 to $121.00 and gave the company a “sector perform” rating in a report on Tuesday, November 3rd. B. Riley restated a “neutral” rating and issued a $101.00 target price on shares of Clorox in a report on Saturday, November 21st. Sanford C. Bernstein upped their price target on Clorox from $111.00 to $116.00 and gave the company a “market-perform” rating in a research note on Tuesday, November 3rd. Deutsche Bank upped their price target on Clorox from $118.00 to $126.00 and gave the company a “hold” rating in a research note on Tuesday, November 3rd. Finally, Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research note on Thursday, November 5th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $117.78.

In other Clorox news, CFO Stephen Robb sold 30,496 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $122.02, for a total transaction of $3,721,121.92. Following the completion of the transaction, the chief financial officer now owns 24,006 shares of the company’s stock, valued at $2,929,212.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jon M. Balousek sold 1,488 shares of the firm’s stock in a transaction on Monday, December 7th. The stock was sold at an average price of $128.69, for a total value of $191,490.72. Following the transaction, the senior vice president now directly owns 10,186 shares of the company’s stock, valued at approximately $1,310,836.34. The disclosure for this sale can be found here.

The Clorox Company (NYSE:CLX) is a United States-based manufacturer and marketer of consumer and professional products. The Company sells its products through mass retail outlets, e-commerce channels, distributors, and medical supply providers. The Company operates through strategic business units that are aggregated into four reportable segments: Cleaning, which consists of laundry, home care and professional products marketed and sold in the United States; Household, which consists of charcoal, cat litter and plastic bags, wraps and container products; Lifestyle, which includes food products, water-filtration systems and filters and natural personal care products, and International, which consists of products sold outside the United States, such as laundry, home care, water-filtration, charcoal and cat litter products, dressings and sauces, plastic bags, wraps and containers and natural personal care products.

12 Month Chart for NYSE:CLX

Receive News & Ratings for Clorox Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Co and related companies with MarketBeat.com's FREE daily email newsletter.